In the BioHarmony Drug Report Database

"Preview" Icon

Lefamulin

Xenleta (lefamulin) is a small molecule pharmaceutical. Lefamulin was first approved as Xenleta on 2019-08-19. It is used to treat bacterial pneumonia in the USA. It has been approved in Europe to treat bacterial pneumonia and community-acquired infections. Xenleta’s patents are valid until 2031-05-23 (FDA).

 

Trade Name

 

Xenleta
 

Common Name

 

lefamulin
 

ChEMBL ID

 

CHEMBL3291398
 

Indication

 

bacterial pneumonia, community-acquired infections
 

Drug Class

 

Antibacterials, pleuromulin derivatives

Image (chem structure or protein)

Lefamulin structure rendering